Highlights from Hematology and Oncology Clinical Trials
This content surveys evidence-based principles in clinical hematology and oncology, centered on how randomized phase III trial design and specific endpoints (progression-free survival, overall survival, objective response rate, pathologic complete response) are used to establish practice-changing therapy. It illustrates several underlying mechanistic and therapeutic frameworks — antibody-drug conjugates, immune checkpoint inhibition stratified by biomarker status, BCL-2 inhibition combined with hypomethylating agents, anti-CD38 monoclonal antibody therapy, and neoadjuvant/total neoadjuvant treatment sequencing — as well as pathophysiological theory of thrombosis (Virchow's Triad) applied to viral-associated coagulopathy. As a domain, it belongs to clinical hematology-oncology and evidence-based medicine, relating trial methodology (randomization, endpoints, biomarker stratification) to the broader discipline of translating molecular and immunologic mechanisms into treatment decisions.